Who
Gregory Scott Duncan
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Dogwood Therapeutics; Director, CorMedix.
In numbers
- Trades disclosed
- 30
- Buys
- 6
- Sells
- 0
- Bought
- $289K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 2 Nov 2020
- Last trade
- 5 Mar 2026
- Last filed
- 6 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Mar 2026filed 6 Mar 2026 | DWTX Dogwood Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —330,000 at $0.00 | filing |
| 5 Mar 2026filed 6 Mar 2026 | DWTX Dogwood Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —330,000 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —30,453 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —30,453 at $0.00 | filing |
| 4 Dec 2025filed 5 Dec 2025 | DWTX Dogwood Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —460,000 at $0.00 | filing |
| 16 Sep 2025filed 18 Sep 2025 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —13,333 at $0.00 | filing |
| 16 Sep 2025filed 18 Sep 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code M | $111K13,333 at $8.32 | filing |
| 27 Jun 2025filed 1 Jul 2025 | DWTX Dogwood Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 17 Jan 2025filed 22 Jan 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 5 Mar 2024filed 20 Mar 2024 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 26 Feb 2024filed 28 Feb 2024 | DWTX Dogwood Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —138,835 at $0.00 | filing |
| 17 Aug 2023filed 18 Aug 2023 | DWTX Dogwood TherapeuticsBiotechnology | SEC FORM 4 Bought | $31K25,000 at $1.25 | filing |
| 14 Jan 2023filed 18 Jan 2023 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 12 Dec 2022filed 15 Feb 2023 | DWTX Dogwood Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —410,000 at $0.00 | filing |
| 12 Dec 2022filed 14 Dec 2022 | DWTX Dogwood Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —480,000 at $0.00 | filing |
| 23 Jun 2022filed 30 Jun 2022 | DWTX Dogwood Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 23 May 2022filed 24 May 2022 | DWTX Dogwood TherapeuticsBiotechnology | SEC FORM 4 Bought | $34K7,500 at $4.52 | filing |
| 22 Feb 2022filed 23 Feb 2022 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 21 Dec 2021filed 22 Dec 2021 | DWTX Dogwood TherapeuticsBiotechnology | SEC FORM 4 Bought | $28K5,000 at $5.52 | filing |
| 21 Jun 2021filed 22 Jun 2021 | DWTX Dogwood Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
News
Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Drop in Short InterestDWTX · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Gregory Scott Duncan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.